Table 3 Designed therapies
Author | Year | Radiotherapy (dose) | Hormone Therapy | Duration | N | Median follow up |
|---|---|---|---|---|---|---|
Zagars | 1988 | 70 Gy | Diethylstilbestrol 25 mg PO qd | Continuously | 82 | 14.5 years |
Laverdiere | 2004 | 64 Gy | Leuprolide 7.5 mg/month + Flutamide | 3 months or 10 months | 161 | 5 years |
Lawton | 2005 | 65 to 70 Gy | Goserelin 3.6 mg/month | Continuously | 977 | 6.5 years |
Granfors | 2006 | 60 to 70 Gy | Orchiectomy | Permanent | 91 | 9.7 years |
See | 2006 | NS | Bicalutamide 150 mg PO qd | Decided by investigator | 1370 | 7.2 years |
D'Amico | 2008 | NS | Goserelin 3,6 mg or Leuprolide 7.5 mg/month + Flutamide | 6 months | 206 | 8.2 years |
Roach | 2008 | 65 to 70 Gy | Goserelin 3.6 mg/month + Flutamide | 3 months | 456 | 11.9 years |
Bolla | 2010 | 70 Gy | Goserelin 3.6 mg/month | 3 years | 415 | 9.1 years |
Denham | 2011 | 66 Gy | Goserelin 3.6 mg/month + Flutamide | 3 months or 6 months | 818 | 10.6 years |
Jones | 2011 | 66.6 Gy | Goserelin 3,6 mg or Leuprolide 7.5 mg/month + Flutamide | 4 months | 1979 | 9.1 years |